Pharmacogenomic testing for major depressive disorder in British Columbia, Canada:Recommendations from a public deliberation

Pharmacogenomic (PGx) testing for major depressive disorder (MDD) can reduce healthcare spending and improve patient outcomes. However, concerns about health equity, data privacy, and secondary usage of data require deliberation. We sought recommendations from members of the general public for policymakers’ consideration.

About C2E2

The Centre for Clinical Epidemiology & Evaluation (C2E2) undertakes research and training and provides evidence-based advice to advance a sustainable health system for British Columbians.

Upcoming Events

Unless otherwise indicated, C2E2 Spotlight is presented on the second Mondays of the month from 12:00pm to 1:00pm in room 700 of the VGH Research Pavilion and/or virtually.

View All Events